Bharatbook announces a report on “Oncology cancer drugs approval profiles”. This Report the specific biochemical interaction through which a drug substance produces its pharmacological effect.
Oncology (1985-2016) – 157 cancer drugs – Ranking and detailed regulatory approval profiles” is a comprehensive drug ranking and profiling report that ranks cancer drugs based on total approvals and unique approvals received in US, Europe and Japan. It provides the regulatory approval details of each drug for the past 30 years (1985-2016) in both the tabular and (an interesting) infographic formats. Additionally, the basic drug-specific information such as first approvals, breakthrough, orphan designations, black box warnings, etc., is also presented along with negative developments of drugs recalled, discontinued and withdrawn.
Part 1: The basic information section covers:
Trade names: Drugs are often known by different brand names (trade names) in different geographies. For instance, Rituxan is the trade name for Rituximab in the US, whereas it is known as Mabthera in Europe. We have presented each drug’s trade name used in different geographies in our report.
Companies involved in marketing: Drugs are often sold or marketed in different geographies by different companies. For instance, Aranesp is marketed in the US and Europe by Amgen, whereas in Japan it is marketed by Kyowa Hakko Kirin.
Active pharmaceutical ingredient: Active pharmaceutical ingredients (API) are the active ingredients in medications, carried by the excipient. In each case, the drug has an API and it has a trade name, by which it is known in the market. For instance, Revlimid is the brand or trade name, whereas lenalidomide is its API.
Therapy segment: We have classified drugs into five major therapy segments ‑ Targeted, Chemo, Hormone, Vaccines and Adjuvants. For instance, Herceptin is a Targeted Therapy drug whereas Zytiga is a Hormone Therapy drug.
Immuno-oncology: This is a growing area of cancer therapy. We have highlighted whether the drugs classified fall under this category or not. For instance, Opdivo is an immuno-oncology drug.
Class of drug: Various therapy segments are further classified into classes of drugs. Monoclonal antibodies, tyrosine kinase and alkylating agent are examples of classes of drugs. Yervoy is a monoclonal antibody whereas Tarceva is a tyrosine kinase inhibitor.
Molecule type: Drugs are classified into two categories, small and large, on the basis of their molecular weight; greater than 900 daltons are large molecules and less than 900 daltons are small molecules. Large molecules are also known as biological drugs. Gazyva is a large molecule drug whereas Imbruvica is a small molecule drug.
Dosage form: We have explained whether the dosage is in the form of vials/injections (injectable) or tablets/capsules (oral). For instance, Tecentriq is an injectable drug whereas Thalomid is an oral tablet.
Route of administration: We have explained whether the drug is taken orally or through the intravenous route. For instance, Empliciti (for multiple myeloma) is taken through the intravenous route.
Mechanism of action: The term mechanism of action refers to the specific biochemical interaction through which a drug substance produces its pharmacological effect. A mechanism of action usually includes mention of the specific molecular targets to which the drug binds, such as an enzyme or receptor.
First approved indication in the geographies US, EU and Japan: Many cancer drugs are often approved for more than one indication. We have highlighted the first approved indication of each drug in the various geographies. For instance, Xeloda was first approved for metastatic breast cancer in the US and Japan whereas, in Europe, it was first approved for colorectal cancer.
Related Reports: Drug Discovery Market Reports